Abstract |
Multifocal avascular osteonecrosis (AON) is a serious manifestation of systemic lupus erythematosus (SLE). Prothrombotic factors, especially antiphospholipid antibodies (aPL), have been associated with the development of AON; therefore, attenuating the procoagulant state while balancing the haemorrhagic risks might have a rationale when managing this condition. We report a case of a 37-year-old patient with SLE, treated with low doses of corticosteroids and immunosuppressive therapy, who was started on vitamin K antagonist following an episode of deep vein thrombosis while having persistent positivity for aPL. After 2 years, he presented with multifocal AON, involving both femurs and shoulders. The patient underwent a bilateral hip replacement, but despite appropriate anticoagulation therapy after 2 years, he developed another episode of AON at both distal epiphyses of the femurs and proximal epiphyses of the tibias. Multifocal AON should be suspected, especially in the presence of aPL positivity. Its aetiology is still unknown and is most likely multifactorial. Its management is challenging and requires combined approaches.
|
Authors | Irene Cecchi, Laura Pérez Sánchez, Savino Sciascia, Dario Roccatello |
Journal | BMJ case reports
(BMJ Case Rep)
Vol. 2018
(Nov 01 2018)
ISSN: 1757-790X [Electronic] England |
PMID | 30389732
(Publication Type: Case Reports, Journal Article)
|
Copyright | © BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ. |
Chemical References |
- Antibodies, Antiphospholipid
- Anticoagulants
- Vitamin K
|
Topics |
- Adult
- Antibodies, Antiphospholipid
(blood)
- Anticoagulants
(therapeutic use)
- Antiphospholipid Syndrome
(complications, diagnosis, drug therapy)
- Diagnosis, Differential
- Humans
- Lupus Erythematosus, Systemic
(complications, diagnosis, drug therapy)
- Male
- Osteonecrosis
(diagnostic imaging, etiology, pathology, surgery)
- Rare Diseases
- Treatment Outcome
- Venous Thrombosis
(complications, drug therapy)
- Vitamin K
(antagonists & inhibitors, therapeutic use)
|